Condition: Hepatocellular Carcinoma Non-resectable · Sponsor: Center Eugene Marquis
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, being the third leading cause of cancer-related death worldwide, with approximately 745 000 deaths reported annually. For advanced patients, including patients with tumoral portal vein thrombosis (PVT), most treatment guidelines recommend systemic therapy, either combination immunotherapy (IO) or combination of immunotherapy and anti-angiogenic treatment for first line option. Results for PVT patients are provided in one trial with a median overall survival of 14.2 months with IO underlying the necessity to improve treatment of PVT patients. Two recent other phase 3 trials also reported positive results for different IO regimen. Selective internal radiation therapy (SIRT) using yttrium-90 (90Y)-loaded glass microspheres (TheraSphereTM) can be used for patients with early stage to locally advanced HCC including PVT patients without extrahepatic spread (EHS). TheraSphereTM is recognized and is reimbursed in France for PVT patients without EHS, since 2019.Several retrospective studies have shown promising results for PVT patients. Nowadays use of SIRT in locally advanced HCC is regaining interest based on the results of the randomized DOSISPHERE-01 study including non-operable patients, about 70% with PVT. This randomized Phase II trial using 90Y-loaded microspheres sought was noted the effectiveness of 90Y-loaded microspheres using a personalized dosimetry approach versus a standard dosimetry approach. …
This description comes directly from the study's public registry record.
Tassadit AMROUN-SEBILLE · 0299253137 · t.amroun-sebille@rennes.unicancer.fr
Valérie Jolaine · 0299253036 · v.jolaine@rennes.unicancer.fr
Always discuss trial participation with your own doctor first.
| CHU de Grenoble | Grenoble, France | Active Not Recruiting |
| CHU de Lille | Lille, France | Active Not Recruiting |
| La Timone | Marseille, France | Not Yet Recruiting |
| CHU de Montpellier | Montpellier, France | Active Not Recruiting |
| CHU de Nice | Nice, France | Active Not Recruiting |
| Centre Eugène Marquis | Rennes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07122089